News

EMD Soreno has recently published Phase 3 clinical data showing that Cladribine tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS). The study, “Reduced brain atrophy rates are associated with lower risk of disability progression…

Multiple sclerosis (MS) patients given gentle electrical stimulation to their tongues during physical and cognitive rehabilitation training benefited more than those who did not have the stimulation, a small pilot study demonstrated. Those who received the weak stimulation had significant improvements in balance and better scores than controls in cognition and other…

A new online resource, LiveWiseMS.org, aims to raise awareness about multiple sclerosis (MS) and provide patients and caregivers information about the disease’s symptoms and conditions. The platform, developed by the International Organization of Multiple Sclerosis Nurses (IOMSN), hopes to promote healthy living and improve quality of life for MS patients and their families.

People with multiple sclerosis (MS) and other chronic diseases value the Affordable Care Act (ACA, also known as Obamacare) more than the general public, concludes a poll conducted by PatientsLikeMe. These patients are also less inclined to repeal Obamacare, and they are more likely to believe Obamacare needs few changes to…

Regular massage therapy given people with multiple sclerosis (MS) significantly reduced their pain and fatigue, and helped to ease spasticity, a small pilot study reports. The results further support previous findings as to the benefits of massage in treating MS symptoms and improving patients’ quality of life. The study, “Impact of Massage Therapy on Fatigue,…

Paeoniflorin (PF), a herb component used in Chinese medicine, improved symptoms and reduced inflammation in a mouse model that recapitulates the human features of multiple sclerosis (MS). The study, “Paeoniflorin Ameliorates Experimental Autoimmune Encephalomyelitis via Inhibition of Dendritic Cell Function and Th17 Cell Differentiation”, appeared in the journal…

A specialty shoe insole that may help multiple sclerosis (MS) patients walk and go about their daily lives with more assurance and ease was developed by an Australian-led research team, which is now seeking 176 patients to test the insole in a three-month trial. The study is led by Anna Hatton, a physiotherapy professor…

Obesity in early adolescence poses a risk for multiple sclerosis (MS) regardless of sex, and an earlier age at puberty also contributes to MS onset at younger ages, especially in overweight teenagers, a study reports. These findings were in the study, “Distinct…

Scientists have discovered the first blood biomarker for multiple sclerosis (MS) –  a chemical identifier in the blood. The discovery should lead to a simple blood test that makes it quicker and easier to follow the course of MS, a debilitating disease of the central nervous system affecting around 2.3 million people…

Ninety-five percent of multiple sclerosis (MS) patients believe medical marijuana should be a treatment option, according to a GeneFo online survey. The survey also showed that almost 73 percent had tried it, even though about half said they hadn’t received information from a doctor about its benefits and risks. A National…

Small natural variations within the DNA sequence of the gene for interleukin-16 (IL-16) were linked to an increased susceptibility to multiple sclerosis (MS) in a small group of Iranian patients. The study, “The Association of Interleukin-16 Gene Polymorphisms with IL-16 Serum Levels and Risk of Multiple Sclerosis,” was published in…

A genome-wide study has identified DNA regions associated with higher levels of circulating cytokines, small proteins that pay a role in inflammatory diseases such as multiple sclerosis (MS). Alterations in the levels and interplay of cytokines and growth factors play a key role in several inflammatory diseases, including MS. Cytokines help regulate…

Switching from Gilenya (fingolimod) to Lemtrada (alemtuzumab) triggers significant and unexpected disease activity in some patients with multiple sclerosis (MS), according to a study published in the scientific journal Neurology Neuroimmunology and Neuroinflammation.

Considerable differences exist in how multiple sclerosis patients, healthcare providers and insurance companies assess the value of current MS treatments, according to a literature review study by the data analysis firm Real Endpoints. For the study, a team of clinicians and researchers looked at more than 300 research articles, covering topics like…

A newly concluded clinical trial gives scientific evidence of the benefits that a stem cell transplant holds for multiple sclerosis (MS) patients who fail to respond to medications — with researchers calling the procedure a reasonable option for those with high disease activity. Five years after the treatment — high-dose immunosuppressive therapy followed by autologous hematopoietic cell transplant — further disease…

Multiple sclerosis (MS) patients who received transcranial direct current stimulation (tDCS) while playing brain-training video games improved their learning and understanding skills to a greater extent than those who only brain-trained. Researchers at NYU Langone’s Multiple Sclerosis Comprehensive Care Center underscored that while more research is needed to explore the procedure’s…

Multiple sclerosis (MS) patients who are showing signs of cognitive impairment may benefit from computer-assisted cognitive rehabilitation programs, according to a new study. Difficulties with short-term memory, or with processing information and concentrating, are believed to affect 40% to 65% of MS patients. Studies have suggested that cognitive rehabilitation may help, and that computer-assisted therapy used…

Continuous treatment with Gilenya (fingolimod) helps limit relapses and detectable lesions in multiple sclerosis (MS) patients, according to a three-year, follow-up study in Japan. The results confirm the findings of trials conducted in predominantly Caucasian populations. The findings were reported in the study, “Long-term efficacy and safety of fingolimod in…

Tecfidera (dimethyl fumarate or DMF) use by multiple sclerosis (MS) patients can result in liver injury and, in rare cases, even severe injury, a study found, leading its researchers to recommend that patients’ on this treatment be carefully monitored for signs of injury. The study, “…

A treatment delivered as a nasal solution helped to preserve eye neurons and improve eyesight in a mouse model of multiple sclerosis (MS), a recent study demonstrated — suggesting that it may be possible to deliver drugs that target the brain in this noninvasive way. But nasal administration is not the only…

More relapsing multiple sclerosis (MS) patients treated with Zinbryta (daclizumab) said they felt its health benefits than did those given Avonex (interferon beta-1a) — demonstrating that patient-reported outcomes do mirror objective measures of improved health in a clinical trial of the two drugs. Patient-reported changes in both physical and psychological health contribute to a more comprehensive picture of…

The University of Saskatchewan‘s incoming Chair in Multiple Sclerosis Clinical Research will have a research endowment worth $8.4 million to help him search for a cure for multiple sclerosis (MS). The school has recruited Michael Levin, MD, an experienced MS researcher, to lead the program for a seven-year term that will begin…

An extension trial assessing generic glatiramer acetate (GTR) treatment in multiple sclerosis (MS) patients found that the formulation is as safe and effective as Copaxone (branded glatiramer acetate), and that switching to GTR is well-tolerated. The findings were in the study, “Switching from branded to generic glatiramer acetate:…

Many multiple sclerosis (MS) patients have a reduced sense of smell, and the more relapses they have, the worse the problem, according to a study suggesting that smell may be a marker for the disease’s progression. Findings also suggested a connection between reduced sense of taste and MS progression. The…

MicroRNAs in the blood could serve as biomarkers to monitor the progression of multiple sclerosis (MS), as well as help identify which mechanisms are at play in each patient, such as inflammation and tissue damage, according to new research. The findings were reported in the study, “Association Between Serum…

Flex Pharma said it plans to prioritize developing its clinical programs in neurological diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and peripheral neuropathies like Charcot-Marie Tooth (CMT). One or two proof-of-concept, Phase 2 clinical trials are planned for this year in the United States to evaluate Flex Pharma’s…

The key to why more women than men develop multiple sclerosis (MS) may be genes that influence physical traits, such as weight, height, and body shape, according to a new study. Researchers caution that the findings need to be verified, but they said processes leading to disease may differ between…

PathMaker Neurosystems and the Brain and Spine Institute (ICM) in Paris will collaborate on human clinical trials to secure CE Mark clearance for PathMaker’s MyoRegulator PM-2200, a noninvasive neurotherapy technology to treat conditions linked to neural pathway disruption, including multiple sclerosis (MS). CE Mark — which stands for “Conformité Européenne,” or European Conformity…

The VA Maryland Health Care System (VAMHCS) and the University of Maryland Fischell Department of Bioengineering are collaborating in a research initiative that aims to increase our understanding of multiple sclerosis (MS). The project is being led by Christopher M. Jewell, PhD, an assistant professor in bioengineering. Jewell will…

Two multiple sclerosis (MS) patients developed severe brain inflammation after being treated with Lemtrada (alemtuzumab), researchers report, raising questions about the therapy. A definite link between the lesions and the treatment, however, was not established. The patients’ symptoms were successfully controlled with a blood transfusion and treatment with rituximab (brand name Rituxan,…